Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

NCT04623541 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT04623541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04623541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Lead sponsor
Genmab
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 25, 2020
Completion date
February 29, 2028
Enrollment
194 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory chronic lymphocytic leukemia, richter's syndrome, small lymphocytic lymphoma, treatment-naïve high risk chronic lymphocytic leukemia